Formulation | 50%Glycerol/H2O(v/v) |
Storage | -20°C |
Purity | >95%bySDS-PAGE |
ActivityDetermination | N/A |
ShelfLife(properlystored) | 12months |
Gel | Novex4-12%Bis-Tris |
---|---|
Load | Bovineosteocalcin,1µgperlane |
Buffer | MES |
Standard | SeeBluePlus2;Myosin(188kDa),PhosphorylaseB(98kDa),BSA(62kDa),GlutamicDehydrogenase(49kDa),AlcoholDehydrogenase(38kDa),CarbonicAnhydrase(28kDa),MyoglobinRed(17kDa),Lysozyme(14kDa),Aprotinin(6kDa),Insulin,Bchain(3kDa). |
Osteocalcin,alsoknownasBone-Gla-Protein(BGP),isasinglechain(Mr=5800)vitaminKdependentproteinproducedbyosteoblastsandfoundinhighconcentrationsinbone(1-4).Post-translationalmodificationbyavitaminKdependentcarboxylaseproducesthreeg-carboxyglutamicacidresiduesatpositions17,21and24.Thematureproteincontains49aminoacidsandasingleintrachaindisulfidebondjoiningCys23toCys29.Thesecondarystructureishighlycalciumdependentandcontains14%α-helix,20%β-sheetand67%randomforminthepresenceofcalcium,and1%α-helix,20%β-sheetand79%randomformintheabsenceofcalcium(4).
BGPbindstophospholipidvesiclesinthepresenceofcalciumions(Kd=6x10-6M)(5).BGPalsobindshydroxyapatiteandisanefficientinhibitorofhydroxyapatiteseededcrystalgrowth,suggestingaregulatoryroleinbonemineralization(6).AlthoughthefundamentalroleofBGPinvivoremainselusive,invitroexperimentationsuggestsrolesinbothboneresorptionandboneformation.BGPhasbeenshowntofunctionasachemo-attractantinaninvitromacrophagemediatedboneresorptionsystem.TheserumconcentrationofBGPhasbeenlinkedtoboneformationrates,andBGPlevelsarecurrentlyusedinresearchassessmentofosteoporosisandothermetabolicbonediseasestates(7).
OsteocalcinispreparedfrombovinebonegenerallyasdescribedbyPriceetal.(1).ThisinvolvesdemineralizationinEDTA,sizeexclusionandionexchangechromatography.Thepurifiedproteinissupplied50%(vol/vol)glycerol/0.01MTris,0.075MNaCl,pH7.4,andshouldbestoredat-20°C.Humanosteocalcinispreparedfromextractsofacid-demineralizedbone,usingimmunoaffinitychromatography.Thehumanproteinissuppliedin0.02MTris,0.15MNaCl,2mMCaCl2,pH7.4andshouldbestoredat-80°C.PurityisdeterminedbySDS-PAGE.
Localization | Bone,plasma | |||||
---|---|---|---|---|---|---|
Modeofaction | Unknown | |||||
Molecularweight | 5,800(1) | |||||
Extinctioncoefficient |
| |||||
Isoelectricpoint | 4.0-4.5(8) | |||||
Structure | Singlechain,oneintrachaindisulfidebond,Cys23-29. | |||||
Percentcarbohydrate | 0% | |||||
Post-translationalmodifications | Threeglaresidues,17,21,24 |
Haemtech生物制药服务(HBS)是一家领先的,符合cGMP要求的QC测试实验室,专门为生产重组和血浆衍生蛋白疗法的生物制药制造商提供分析服务,重点是那些会影响止血系统的药物。HBS使客户能够满足法规和质量测试要求,从而将其候选药物从开发转向商业化。
对生物制药的需求正在增长,并且该行业正在迅速采用外包策略,以作为满足不断升级的监管要求的一种方式。凭借在止血方面的丰富经验,HBS能够很好地协助开发影响凝血系统的药物产品。